Language:

Bladder cancer

The Lancet (British edition), 2016-12, Vol.388 (10061), p.2796-2810 [Peer Reviewed Journal]

Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Dec 3, 2016 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)30512-8 ;PMID: 27345655 ;CODEN: LANCAO

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Bladder cancer
Author: Kamat, Ashish M, Prof ; Hahn, Noah M, MD ; Efstathiou, Jason A, MD ; Lerner, Seth P, Prof ; Malmström, Per-Uno, Prof ; Choi, Woonyoung, PhD ; Guo, Charles C, MD ; Lotan, Yair, Prof ; Kassouf, Wassim, MD
Subjects: Antineoplastic Agents - administration & dosage ; Bladder cancer ; Cancer therapies ; Carcinoma - diagnosis ; Carcinoma - genetics ; Carcinoma - pathology ; Chemotherapy ; Cisplatin - administration & dosage ; Combined Modality Therapy ; Cystectomy - methods ; Disease-Free Survival ; Hematuria - etiology ; Humans ; Immunotherapy ; Internal Medicine ; Metastasis ; Mutation ; Neoplasm Invasiveness - pathology ; Patients ; Treatment Outcome ; Tumors ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - genetics ; Urinary Bladder Neoplasms - pathology
Is Part Of: The Lancet (British edition), 2016-12, Vol.388 (10061), p.2796-2810
Description: Summary Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy. For muscle-invasive bladder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure. Selected patients with muscle-invasive tumours can be offered bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation. Advanced disease is best treated with systemic cisplatin-based chemotherapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemotherapy cannot control the disease. Developments in the past 2 years have shed light on genetic subtypes of bladder cancer that might differ from one another in response to various treatments.
Publisher: England: Elsevier Ltd
Language: English
Identifier: ISSN: 0140-6736
ISSN: 1474-547X
EISSN: 1474-547X
DOI: 10.1016/S0140-6736(16)30512-8
PMID: 27345655
CODEN: LANCAO
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Bladder cancer

Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Dec 3, 2016 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)30512-8 ;PMID: 27345655 ;CODEN: LANCAO

Searching Remote Databases, Please Wait